Exploring anti-liver cancer targets and mechanisms of oxyresveratrol: in silico and verified findings

Abstract

The aim of current study was to exhume the potential targets and molecular mechanisms of oxyresveratrol, a structurally re-constructed resveratrol, for treating liver cancer through bioinformatics investigation and experimentative validation. To start with, the network pharmacology approach and molecular docking technology were used to uncover all candidate targets of oxyresveratrol to treat liver cancer, accompanied with identified anti-liver cancer targets including estrogen receptor 1 (ESR1), epidermal growth factor receptor (EGFR). In addition, more pharmacological mechanisms of oxyresveratrol against liver cancer were revealed in details. In experimental verification, the clinical samples of liver cancer showed elevated ESR1, EGFR mRNA expressions. The in-vitro data indicated that intracellular contents of ESR1, EGFR mRNAs in oxyresveratrol-treated liver cancer cells were reduced. Taken together, the bioinformatics and validated findings have highlighted detailed pharmacological targets and molecular mechanisms of oxyresveratrol for treating liver cancer. Following with experimental verification, the identified genes of ESR1, EGFR may function as potential screening anti-liver cancer markers.

Assessment of disease control rate and safety of sorafenib in targeted therapy for advanced liver cancer

“…When evaluating the median survival time for a specific cancer type, it is generally calculated from the time of tumor detection. DPT refers to the time from randomization to objective tumor progression [33,34]. Therefore, these results indicate that the addition of sorafenib treatment on top of TACE can effectively prolong the ST of patients with ALC and delay the progression of the disease.…”

Comparative Studies of Resveratrol, Oxyresveratrol and Dihydrooxyresveratrol on Doxorubicin-Treated Lung Cancer Cells

“…RES and Oxy-RES have been mentioned to inhibit the gene expression of cancer stem cell markers, these can make cancer stem cells turn to a hypoxia-associated tumor [ 38 ]. Oxy-RES has been reported for anti-liver cancer pharmacological targets through down regulation of (1) estrogen receptor 1 (ESR1) found in primary malignancy and during metastasis (2) epidermal growth factor receptor (EGFR) which is responsible for cell proliferation and signal transduction (3) vascular endothelial growth factor (VEGF) receptor 3 and VEGF-C which can lead to the inhibition of both angiogenesis and lymph node metastasis [ 39 ]. Oxy-RES has been demonstrated to inhibit human colon cancer cell migration [ 40 ], human bladder cancer cell growth [ 41 ] and human breast cancer cell cycle [ 42 ].…”

Recent progress in nanotechnology-based drug carriers for resveratrol delivery

“…RES also exhibits significant neuroprotective effects in central nervous system diseases, such as Alzheimer’s disease (Huang et al., 2021 ), by inhibiting microglial activation and modulating neuroinflammation (Moradi et al., 2020 ). It can protect against cancers of the breast (Vargas et al., 2020 ), prostate (Khusbu et al., 2020 ), lung (Yousef et al., 2017 ), colon (Yuan et al., 2019 ), liver (Zhao et al., 2021 ), gastrointestinal tract (Xu et al., 2017 ), pancreas (Srivani et al., 2020 ), ovary (Guo et al., 2015 ), and skin (Iqubal et al., 2021 ).…”